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Abstract: Adiponectin is secreted by white adipose tissue and exists as the most abundant adipokine in the human plasma. Recent 
research has indicated that plasma adiponectin levels are inversely correlated with body mass index (BMI) and insulin resistance. 
Reduction of plasma adiponectin levels is commonly observed in the patients with type 2 diabetes (T2D) and/or in those who are 
obese in comparison with healthy control individuals. The adiponectin (AdipoQ) gene has a moderate linkage disequilibrium (LD), 
but two small LD blocks are observed, respectively, in the promoter region and the boundary of exon 2-intron 2. Genetic association 
studies have demonstrated that single nucleotide polymorphisms (SNPs) +45G15G(T/G) in exon 2 and +276G/T in intron 2 of the 
AdipoQ gene confer the risk susceptibility to the development of T2D, obesity and diabetic nephropathy (DN). The SNPs in the pro-
moter region, including -11426A/G, -11377C/G and -11391G/A, are found to be associated with T2D and DN. Recent research has 
indicated that the promoter polymorphisms interfere with the AdipoQ promoter activity. The haplotypes constructed by the promoter 
polymorphisms and SNP +276G/T in intron 2 are associated with circulating adiponectin levels. This review summarises genetic and 
pathophysiological relevancies of adiponectin and discusses about the biomarkers of adiponectin plasma protein variation and genomic 
DNA polymorphisms.
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Introduction
Adipose  tissue  or  fat  is  a  loose  connective  tissue 
composed  of  adipocytes.  Its  main  role  is  to  store 
triglyceride (TG) and to release free fatty acid/glycerol 
in response to changing energy demands. In humans, 
adipose tissue is located beneath the skin (subcuta-
neous fat), around internal organs (visceral fat), and 
in  the  bone  marrow  (yellow  bone  marrow). There 
exit two types of adipose tissue: white adipose tissue 
(WAT)  and  brown  adipose  tissue  (BAT).  Adipose 
tissue also serves as an important endocrine organ,1 
because several hormones (adipokines) such as leptin 
(OMIM 164160),2 adipsin (OMIM 134350),3 tumor 
necrosis factor-alpha (OMIM 191160),4 and adipo-
nectin  (OMIM  605441),5  are  found  to  be  secreted 
by the tissue into the bloodstream. The leptin gene 
was identified in 1994.6 In one year later, adiponectin 
was found as the most abundant adipokine and count 
for 0.01% or 3–30 µg/ml of total plasma protein.7–10 
In comparison with leptin research, however, until the 
recent 8 years, adiponectin has been attracted much 
attention particularly in the fields of pathophysiology 
and genetics of type 2 diabetes (T2D), obesity and 
diabetic  nephropathy  (DN).  In  this  review,  I  will 
summarise genetic and pathophysiological relevancies 
of  adiponectin  and  discuss  about  the  biomarkers 
of  its  plasma  protein  variation  and  genomic  DNA 
polymorphisms.
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Figure 1. Genomic DNA, mRNA and protein of adiponectin.
Adipose  tissue  is  an  endocrine  organ,  and 
adiponectin is the most abundant adipokine secreted 
by white adipose tissue (WAT) into the bloodstream.
Genomic  DnA  structure,  mRnA 
and protein of Adiponectin
The  adiponectin  gene  (GeneID  9370)  has  been 
recently encoded by AdipoQ (adiponectin, C1q and 
collagen domain containing). The alternative names 
for  adiponectin  gene  are  ACDC,  APM1,  ACRP30 
and  GBP28.  Figure  1  demonstrates  the  molecular 
structures of genomic DNA (NT_005612.15), mRNA 
(NM_004797.2)  and  protein  (NP_004788.1)  of 
adiponectin. The AdipoQ gene spans 1.579 kb and 
contains 3 exons. The translation start point is located 
in exon 2. The promoter region required for the AdipoQ 
gene  includes  up-strand  sequence,  5’-untraslated Biomarkers of adiponectin
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region (5’-UTR) and intron 1. The promoter region 
from  –676  to  +41  has  found  to  be  sufficient  for 
basal transcriptional activity, in which two elements 
i.e.  sterol  regulatory  binding  protein  (SREBP, 
from -431 to -423) and CCAAT/enhancer binding 
protein  (C/EBP,  from  –230  to  –224)  reside.11–19 
Adiponectin protein is constructed by 244 amino acids 
at a molecular weight of 26,414 Da, and consists of 
collagen-like fibrous and C1q-like globular domains. 
Sequence  analysis  predicted  that  the  protein  has 
a signal peptide but no transmembrane hydrophobic 
stretch,  and  a  short  N-terminal  non-collagenous 
sequence  followed  by  a  short  collagen-like  motif 
of  G-X-Y  repeats.  Adiponectin  exists  mainly  as 
full-length in plasma. The small fragment of globular 
form is also found in plasma most likely due to the 
cleavage  of  adiponectin  by  leukocyte  elastase.20–22 
Northern blot analysis detected a 4.5-kb adiponectin 
transcript in adipose tissue but not in muscle, intestine, 
placenta,  uterus,  ovary,  kidney,  liver,  lung,  brain 
or heart.23,24 The AdipoQ mRNA in human (Homo 
sapiens) has the relatively high identical homology 
respectively with chimpanzee (Pan troglodytes, 99%), 
cattle (Bos Taurus, 87%), pig (Sus scrofa, 87%), dog 
(Canis familiari, 87%), mouse (Mus musculus, 84%) 
and rat (Rattus norvegicus, 83%). Adiponectin expres-
sion is regulated by Peroxisome proliferator-activated 
receptor-gamma  (PPAR γ)-dependent  pathways. 
PPAR γ  ligands  increase  expression  and  plasma 
concentration of adiponectin.25–27
plasma protein Levels and Disease 
Relationships for Adiponectin
There is no significant gender difference of plasma 
adiponectin levels in gender for newborn infants.28–31 
However,  plasma  adiponectin  levels  were  inversely 
correlated with obesity and insulin resistance in boys and 
girls.32 Adiponectin values is found to be decreased in 
the children whose body mass index (BMI) increased.33 
Sex differences in adiponectin are dependent on both 
puberty stage and adiposity in adolescents.34 In adult, 
adiponectin expression from adipose tissue is higher 
in lean subjects and women, and is associated with 
higher degrees of insulin sensitivity.35
Reduction  in  plasma  adiponectin  levels  are 
commonly  observed  in  several  metabolic  disorders 
related with insulin resistance, including T2D and/or 
obesity, in both children and adults.36–41 Pima Indians 
in Arizona suffer from a high prevalence of T2D, 
which  is  associated  with  obesity.  Their  levels  of 
plasma  adiponectin  are  significantly  depressed.42 
Women  with  prior  gestational  diabetes  mellitus 
(pGDM) are at increased risk of development of T2D, 
and they also had lower plasma adiponectin concen-
trations compared with unaffected women.43,44 Evide-
nce has also indicated that plasma adiponectin levels 
independently correlate β-cell function in late pregnacy 
of  diabetic  patients. Thus,  adiponectin  may  play  a 
role on not only mediating insulin resistance but also 
β-cell dysfunction in the pathogenesis of diabetes.45 
Furthermore,  lower  plasma  adiponectin  levels  and 
insulin resistance coexist in a genetically prone sub-
set of first degree African-American relatives before 
development of impaired glucose tolerance (IGT) and 
T2D with risk of diabetes.46 The patients with T2D not 
only have a decreased adiponectin levels in the basal 
state but also have impaired utilization of adiponec-
tin in the coronary artery and/or the heart, which may 
promote the development of atherosclerosis.47,48
Plasma adiponectin levels are inversely correlated 
with body mass index and insulin resistance. Type 
2 diabetes patients and obese subjects often have 
lower plasma adiponectin levels.
Interestingly,  plasma  adiponectin  concentrations 
in the patients with type 1 diabetes (T1D) are found 
to  be  significantly  elevated  in  relation  to  healthy 
controls.49–52 In the patients with macroalbuminuria, 
progression  to  end-stage  renal  disease  (ESRD)  is 
found to be associated with higher serum adiponectin 
levels.53,54  Interrelations  between  adiponectin  and 
inflammation,  dyslipidemia,  C-peptide  levels  and 
sex appear to be important for complex adiponectin 
modulation  and  action.  The  association  between 
C-peptide  and  adiponectin  is  probably  one  of  the 
reasons for their different respective levels between 
T1D  and  T2D.  Development  of  hyperglycemia  is 
often  accompanied  by  dyslipidemia,  hypertension 
heighten inflammation, endothelial dysfunction and 
coagulant activity, whereas adiponectin is involved in 
the pathophysiological mechanisms.55–58
Plasma  adiponectin  levels  in  type  1  diabetes 
patients and in the patients with nephropathy are 
increased compared to non-diabetic individuals orGu
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Accumulating  evidence  shows  that  adiponectin 
plays an important role on insulin sensitivity, insulin 
ressistance  and  β-cell  dysfunction.  Reduction  of 
plasma/serum  adiponectin  levels  is  significantly 
related to the development of diabetes, obesity and 
insulin resistance. Adiponectin in human serum forms 
a wide range of multimers from trimers and hexamers 
(low and/or medium molecular weight, LMW/MMW) 
to high molecular weight (HMW) dodecamers and 
18 mers. Almost all adiponectin in plasma appears to 
exist as full-length adiponectin molecule.59–61 Recent 
research  has  indicated  that  HMW  adiponectin  has 
bioactivity. Serum HMW adiponectin is related to early 
postprandial glycemic increases and gastric emptying 
in T2D patients.61,62 However, a comparative evaluat-
ion study with the limited number of subjects (n = 60) 
does not support the superiority of HMW over total 
adiponectin in assessing metabolic variables at baseline 
or in response to physical training.63 Therefore, evalu-
ation of serum adiponectin levels by using the ratio of 
HMW/(LMW + MMW) in the patients with diabetes, 
obesity, diabetic nephropathy and healthy individuals 
is of importance to better understand the role of adipo-
nectin on the development of these complex diseases.
Genetic polymorphisms of the AdipoQ 
Gene and clinically Associated 
with Diseases
The  AdipoQ  gene  is  located  on  chromosome  3q27. 
Genome wide scan studies indicate that a susceptibility 
locus linked to T2D, obesity and coronary heart dis-
ease may reside in this chromosomal region.64–71 Based 
on  biological  evidences  and  positional  information 
from linkage studies, the AdipoQ gene is considered as 
an important candidate for T2D. Mutation screening 
for the AdipoQ gene in T2D has been done and a total 
of 42 single nucleotide polymorphisms (SNPs) with 
minor allele frequency (MAF)  1.5% are represented 
in  Table  1.  The  linkage  disequilibrium  (LD)  of  the 
AdipoQ gene is moderate, but there are two small LD 
blocks, one including SNPs in the promoter region and 
another one spanning the boundary of exon 2-intron 2.72 
In the recent 8 years, a number of genetic association 
studies for the AdipoQ gene polymorphisms in T2D, 
obesity  and  other  metabolic  disorders  have  been 
reported, and the references are selected in this review. 
Genetic association of SNPs in the AdipoQ gene with 
T2D, obesity and DN in different ethnic populations 
is summarized in Table 2. There are two independent 
association  signals,  which  are  represented  in  these 
two LD blocks.73 The SNPs i.e. +45T/G and +276G/T 
in the AdipoQ gene are the common polymorphisms 
associated with T2D, obesity and insulin resistance.74–81 
A haplotype defined by these two SNPs is found to be 
strongly associated with many components of insulin 
resistance  syndrome.73,82  However,  association  of 
+45T/G and +276G/T polymorphisms with T2D is not 
seen in French and Swedish Caucasians. Instead, SNP 
-11377C/G, -11426A/G and -11377C/G in the prom-
oter region of the AdipoQ gene are found to be strongly 
associated with T2D in French and Swedish Cauca-
sians.83–85  These  three  promoter  polymorphisms  are 
constructed as a LD block and their haplotypes are asso-
ciated with type 2 diabetes and affect the promoter acti-
vity.86 Non-synonymous SNPs in the C1q-like globular 
domain have relatively low MAFs (1.5%). H111Y is 
an unique non-synonymous SNP with MAF  1.5% 
and found to be significantly associated with low plasma 
adiponectin levels, BMI and T2D.87 Genetic association 
studies have clearly demonstrated that the AdipoQ gene 
DNA polymorphisms have genetic effects on diabetes, 
obesity  and  insulin  resistance,  which  are  influenced 
by  different  genetic  backgrounds  and  environmental 
factors in different ethnic populations.
Both  T1D  and  T2D  are  heterogeneous  disor-
ders and the heterogeneity affects the insulin secre-
tion  and  insulin  action  in  glucose  metabolism. 
Epidemiological  studies  indicate  that  there  is  the 
association between T1D and T2D.88 Adiponectin has 
a role on β-cell dysfunction.89,90 However, whether 
the AdipoQ gene also confers genetic susceptibility 
to development of T1D is unknown. A recent genetic 
association study of the AdipoQ gene in Swedish T1D 
patients  has  been  performed.  Results  indicate  that 
SNPs  +45G15G(T/G)  and  +276(G/T)  are  strongly 
associated with T1D. Analyses based on haplotypic 
genotypes  (diplotypes)  constructed  with  these  two 
SNPs including +45T/G and +276G/T and another 
two promoter SNPs i.e. -11426(A/G), -11377(G/C) 
indicated  that  common  haplotypes  are  associated 
with T1D.91 Thus, the AdipoQ gene may confer the 
the  patients  without  nephropathy.  The  possible 
mechanism concerning different adiponectin levels 
in type 1 and type 2 diabetes is due to adiponectin 
modulation and action in related to C-peptide.Biomarkers of adiponectin
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Table 1. Single nucleotide polymorphisms in the adiponectin gene.
snp ID snp type* Region contig position** Heterozygosity
rs16861194 R = A/G 5'-end -11426 93054575 0.283
rs17300539 R = A/G 5'-end -11391 93054610 0.045
rs266729 S = C/G 5'-end -11377 93054624 0.368
rs182052 R = A/G Intron 1 93055932 0.486
rs710445 R = A/G Intron 1 93056668 0.498
rs16861205 R = A/G Intron 1 93056784 0.251
rs16861209 M = A/C Intron 1 93058264 0.052
rs822391 Y = C/T Intron 1 93058953 0.160
rs822393 Y = C/T Intron 1 93061476 0.490
rs16861210 R = A/G Intron 1 93061648 0.131
rs822394 M = A/C Intron 1 93061878 0.121
rs822395 M = A/C Intron 1 93061957 0.417
rs822396 R = A/G Intron 1 93062027 0.238
rs17366499 R = A/G Intron 1 93062224 0.014
rs12495941 K = G/T Intron 1 93063330 0.453
rs7649121 w = A/T Intron 1 93063935 0.422
rs7627128 M = A/C Intron 1 93063949 0.369
rs9877202 R = A/G Intron 1 93064757 0.114
rs2036373 K = G/T Intron 1 93065341 0.061
rs17366568 R = A/G Intron 1 93065603 0.068
rs16861220 R = A/G Intron 1 93065662 0.014
rs16861222 Y = C/T Intron 1 93065691 0.014
rs17366653 Y = C/T Intron 1 93065966 0.014
rs182052 R = A/G Intron 1 93055932 0.486
rs710445 R = A/G Intron 1 93056668 0.498
rs2241766 K = G/T G45G exon 2 93066942 0.397
rs1501299 M = A/C Intron 2 +276 93066273 0.426
rs2241767 R = A/G Intron 2 93066346 0.242
rs3821799 Y = C/T Intron 2 93066636 0.496
rs3774261 R = A/G Intron 2 93066709 0.499
rs3774262 R = A/G Intron 2 93066964 0.239
rs17366743 Y = C/T H111Y exon 3 93067239 0.046
rs4068 Y = C/T 3'-UTR 93067708 0.014
rs1501298 Y = C/T 3'-UTR 93067792 0.393
rs6444172 M = A/C 3'-UTR 93068221 0.014
rs6444174 Y = C/T 3'-UTR 93068339 0.117
rs6773957 R = A/G 3'-UTR 93068855 0.499
rs1063537 Y = C/T 3'-UTR 93069225 0.242
rs2082940 Y = C/T 3'-UTR 93069314 0.312
rs1063538 Y = C/T 3'-UTR 93069333 0.499
rs1063539 S = C/G 3'-UTR 93070542 0.251
rs9842733 w = A/T 3'-UTR 93070632 0.074
notes: *The codes of SNP types are designed by American Association of Biochemistry. **The contig reference ID is NT_005612.15. Data are represented 
from dbSNP database. Those six SNP with bold ID numbers are found to be importantly associated with metabolic disorders.Gu
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Table 2. Association between adiponectin genetic polymorphisms and metabolic disorders.
snp clinically associated ethnic group
rs16861194 Adiponectin levels French Caucasians, Swedish,
-11426 A/G Type 2 diabetes european Caucasians
rs17300539 Adiponectin levels French Caucasians
-11391 A/G Type 2 diabetes UK Caucasian women
Obesity German, Italian
Insulin resistance Black South Africans
Insulin sensitivity Spanish, Polish
Diabetic nephropathy
rs266729 Adiponectin levels French Caucasians
-11377 C/G Type 2 diabetes Swedish, Danish
Obesity German, Italian
Insulin resistance Black South African
Insulin sensitivity Chinese, Spanish
Diabetic nephropathy Polish
rs2241766 Adiponectin levels Japanese, Chinese
G/T G45G Fasting glucose levels Korean, Italian
Type 2 diabetes Quebec family study
Obesity Uygurs, Swedish, Finnish
Insulin resistance African Americans
Insulin sensitivity Spanish, German
Diabetic rentiopathy european Caucasians
Diabetic nephropathy Polish
Atherosclerosis
Cardiovascular diseases
rs1501299 Adiponectin levels european Caucasians
+276 A/C Type 2 diabetes Japanese, Italian, German
Obesity Chinese, Korean
Insulin resistance Quebec family study
Insulin sensitivity Swedish, Finnish
Diabetic nephropathy African Americans
Polycystic ovary 
syndrome
Uygurs, Chinese, Spanish 
Polish
Cardiovascular diseases
rs17366743 Adiponectin levels German, Polish
C/T H111Y Body mass index Finnish
Type 2 diabetes Framingham Americans
common susceptibility in the development of both 
T1D and T2D.
Interestingly, +276(G/T), as a putative functional 
SNP (pf-SNP), is found to be associated with plasma 
adiponectin  levels  in  T2D,74  T1D91  and  also  in 
nonalcoholic steatohepatitis (NASH).92 The promoter 
polymorphisms, including -11426A/G, -11377C/G 
and -11391G/A, are also found to be associated with 
are associated with circulating adiponectin levels in 
diabetes and obesity. The haplotype with the minor 
allele in all three promoter polymorphisms show a 
complete loss of promoter activity.83,85,86 Thus, SNPs 
in the promoter and intron 2 in the AdipoQ gene play 
a functional role on the regulation of adiponectin.Biomarkers of adiponectin
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Evidence indicates that the putative functional SNP 
(pf-SNP)  +276G/T  and  promoter  polymorphisms 
in the AdipoQ gene are associated with circulating 
adiponectin levels. These polymorphisms functionally 
regulate adiponectin promoter activity and its protein 
levels in blood. Knowledge of cellular mechanism how 
these polymorphisms regulate plasma adiponectin 
levels is still limited.
Although  association  of  the  AdipoQ  genetic 
variation with plasma adiponectin levels in T2D and 
T1D has been well studied, further investigation is 
still under consideration in order to fully understand 
the relationship between genetic role and biological 
regulation  of  adiponectin.  Indeed,  regulation  of 
plasma adiponectin levels is complex and it is under 
a multigenic control. Recent research has indicated 
that PPAR γ (P12A) and IRS-1 (G972R) genetic poly-
morphisms interacts the influence plasma adiponectin 
concentrations  in  young  Finnish  men.98 A  linkage 
analysis reveals that there are two additional loci on 
chromosomes 14q13 and 5p15 except of the AdipoQ 
and PPAR γ genes are linked with plasma adiponectin 
levels.99 Identification of the genes in chromosomal 
fragments of 14q13 and 5p15 that are linked to plasma 
adiponectin levels may provide further information 
for better understanding regulation of adiponectin.
This figure is modified from Zhang et al 2009. 
The partial sequence from Homo sapiens adiponec-
tin  promoter  (AJ011119.1,  GI:  5823971)  is  repre-
sented. Three adiponectin promoter polymorphisms 
SP1
TTTGGAACGGCCCCAATTTA……TGATCTGCCCGCCTC……TCCTAAGCCCTTGCTGGGGTC
525–530
–11426 A/G –11391 A/G –11377 C/G
SP1(+/–)
GTAA/GTTTAATTCATCAGAATGTGTGGCTTGCAAGAACCG/A GCTCAGATCCTGCC/GCTT
1760–1765
SP1
CAAAAACAAAACA……CTGCCAGGGACATGTGCCTGCCCACCGGCCTCTGGCCCTC……TG
2668–2673
SP1
AGGTGGGGACTGCCTGCCCCCGTGAGTA……TCGACCAGCAGGCA
2736–2741 
Figure 2. The adiponectin promoter polymorphisms and the binding sites for transcriptional factor SP1.
It has been demonstrated that SP1 belongs to the SP 
family of transcriptional factors, and is ubiquitously 
expressed  in  mammalian  cells.93,94  Barth  et  al  have 
previously reported that SP1 binding activity is enhan-
ced during adipocyte differentiation, and has stimula-
tory  effects  on  the  adiponectin  promoter  activity.95 
Figure  2  represents  the  promoter  sequence  and  its 
polymorphisms in the AdipoQ gene. Recently, evidence 
has indicated that the allele G of SNP -11377C/G alters 
the sequence for one of four SP1 binding sites.96 The risk 
G allele results in abolishing of SP1 binding and sub-
sequently causes reduction of adiponectin activity by 
~25%.82 Beside SNP -11377C/G, -11391A/G is another 
promoter polymorphism and has moderate association 
with T1D diabetic nephropathy among Danish cohort 
but not in Finnish and French populations.97 Further 
investigation  for  understanding  correlation  between 
these two promoter polymorphisms and novel binding 
site has been taken into our consideration.
Promoter  polymorphism  -11377C/G  resides 
one  of  transcriptional  stimulatory  protein  (SP1) 
binding  sites.  The  G  allele  interfere  the  binding 
function and consequently reduces the adiponectin 
promoter activity.Gu
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including -11426A/G, -11391G/A and -11377C/G 
are shown with block and italic letters. The binding 
sites for transcriptional factor SP1 are indicated with 
block  letters  and  underline.  Four  binding  sites  for 
SP1 are located in g.525–530, 1760–1765, 2668–2673 
and  2736–2741.  SNP-11377C/G  is  involved  in 
the sequence of SP1 transcriptional binding site at 
g.1760–1765. SP1 binding activity is enhanced dur-
ing  adipocyte  differentiation,  and  has  stimulatory 
effects on the adiponectin promoter activity (Barth et 
al 2002). The allele G of SNP -11377C/G alters the 
sequence for one of SP1 binding sites, which results 
in reduction of the adiponectin promoter activity by 
~25% (Bouatia-Naji et al 2006).
summary
Taking  together,  biological  and  genetic  studies 
have demonstrated that adiponectin plays an impor-
tant  role  in  pathogenesis  of  diabetes,  obesity  and 
insulin  resistance.  Plasma  adiponectin  levels  are 
significantly  decreased  in  T2D  patients  and  obese 
subjects compared to the healthy individuals. Genetic 
polymorphisms in LD blocks of the AdipoQ gene, 
including the promoter region and the boundary of 
exon 2-intron 2, are associated with T2D, obesity, 
DN and insulin resistance. Therefore, plasma/serum 
adiponectin levels and genomic DNA polymorphisms 
in the AdipoQ gene can be used as the biomarkers 
for early diagnosis and clinic prediction of diabetes, 
obesity,  diabetic  complications  and  other  meta-
bolic disorders. Evaluation of adiponectin levels with 
the ratio of HMW/(LMW and MMW) and consider-
ation of different ethnic genetic backgrounds are of 
importance in the translation research of adiponectin.
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